Jubilant Ingrevia Ltd. · NSE:JUBLINGREA

Jubilant Ingrevia — Q2 FY2023 Earnings Presentation

41 slides from Jubilant Ingrevia's earnings presentation, October 2022

  1. Slide 1: Investor Presentation

    Investor Presentation October 2022

  2. Slide 2: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  3. Slide 3: Company Overview

    Company Overview

  4. Slide 4: Jubilant Bhartia Group - Snapshot

    Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod

  5. Slide 5: Integrated Business Model

    Integrated Business Model Jubilant Ingrevia Integrated Operations… 42% of our Pyridine & Picolines Speciality Nutrition & Health Chemical volume is used in-house for value- Chemicals Solutions Intermediates# added products in Speciality Nutrition & Pyridine & Chemicals & for Vitamin B3 Nutrition & H

  6. Slide 6: Glorious Four Decades of Growth

    Glorious Four Decades of Growth Commissioning of Our Journey 10+ years experience in 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) Phase1: Diketene 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ Derivative Plant Vitamin B3 2022 2017: Certified for Responsible Care

  7. Slide 7: Executive Leadership Team

    Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 35 years of industry experience Anil Khubchandani Chandan Singh Sumit Das Ashish Kumar Sinha Co-CEO & WTD Co-CEO SVP – Nutrition & VP – Animal & Human Speciality Chemicals Chemical Intermediates Health Ingredient

  8. Slide 8: Multi Location Manufacturing & Operation Excellence

    Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, Maharashtra, India Speciality Chemicals, Chemical Intermediates

  9. Slide 9: Research Development & Technology (RDT)

    Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 92 highly qualified scientists (22 PhDs) 45 Products in Pipeline for next 4 yea

  10. Slide 10: End Usage Applications for Pharma, Agrochemicals & Nutraceuticals

    End Usage Applications for Pharma, Agrochemicals & Nutraceuticals Therapeutic Category Our Product Category (GMP & Non-GMP) (Used in ~ 53 APIs) Pyridine, Picolines Amino Methyl Chloro/ Bromo/ Pyridines Fluoro Pyridines Antipyretic Analgesic Antifibrosis Off- Patented Amino Pyridines Hydroxy Methyl P

  11. Slide 11: Financial Highlights: Q2 & H1 FY'23

    Financial Highlights: Q2 & H1 FY’23

  12. Slide 12: Chairmen's Message on Q2 & H1 FY23 Financial Results

    Chairmen’s Message on Q2 & H1’FY23 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are pleased to announce stable operational and financial performance during the quarter under review, despite continuing headwinds on account of higher energy costs during the current

  13. Slide 13: Financial Highlights: Key Financial Parameters

    Financial Highlights1 : Key Financial Parameters Highlights ₹ 1,304 Cr. ₹ 160 Cr. 12.3% ₹ 84 Cr. 6.5% ₹ 5.3 Q2’FY23 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 7% YoY (21)% YoY (426) bps (24)% YoY (260) bps (24)% YoY Highlights ₹ 1,223 Cr. ₹ 202 Cr. 16.5% ₹ 111 Cr. 9.1% ₹ 7.0 Q2’FY22 Sales EBITDA EBITDA

  14. Slide 14: Q2 FY'23 Financial Results Summary

    Jubilant Ingrevia – Q2 FY’23 Financial Results Summary Particulars1 Q2'FY22 Q2'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 295 480 63% • Overall Revenue grew by 7% on YoY basis, led by higher sales Nutrition & Health Solutions 179 114 (36%) performance of Speciality Chemical Busin

  15. Slide 15: H1 FY'23 Financial Results Summary

    Jubilant Ingrevia – H1 FY’23 Financial Results Summary Particulars1 H1'FY22 H1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 600 863 44% • Overall Revenue grew by 4% on YoY basis, mainly due to higher sales Nutrition & Health Solutions 346 264 (24%) performance by Speciality Chemica

  16. Slide 16: Debt Profile – As on 30th September, 2022

    Debt Profile – As on 30th September, 2022 Particulars1 30-Sep-21 31-Mar-22 30-Sep-22 Long Term Borrowings 218 100 - Short Term Borrowings 45 129 384 Total Gross Debt 263 229 384 Cash & Equivalent 70 49 102 Total Net Debt 193 181 282  We have completely paid off our high cost long term borrowing res

  17. Slide 17: Balance Sheet – Key Parameters/Ratios (Pro-Forma)

    Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) Return on Equity 27.8% 21.9% (%age) 20.2% (%age) 18.9% 16.4% 14.5% FY'21 FY'22 H1'FY23 FY'21 FY22 H1'FY23 Asset / Turnover and Return On Asset (RoA) Net Working Capital 15.0% 16.2% 17.9% 55 Days 59 Day 65 2.0x 2.8x

  18. Slide 18: Business Segments Overview

    BUSINESS SEGMENTS OVERVIEW

  19. Slide 19: Speciality Chemicals – Segment Snapshot

    Speciality Chemicals – Segment Snapshot Geographical Revenue Split (H1’FY23) 70+ Products (Pyridines & Picolines, Globally among Top 2 in Globally lowest cost Domestic Sales Cyanopyridines, (Pyridine+Beta); for International producer of Pyridine Piperidines, Consumption Globally #1 in 17 Pyridine of

  20. Slide 20: Speciality Chemicals Segment Highlights – Q2 FY'23

    Speciality Chemicals Segment Highlights – Q2 FY’23 Particulars 1 Q2'FY22 Q2'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 295 480 63%  Specialty Chemicals revenue grew by 63% on YoY basis driven by higher Reported EBITDA 71 77 8% volume across product segments Reported EBITDA Margin (%) 24.1% 16.0%  S

  21. Slide 21: Speciality Chemicals Segment Highlights – H1 FY'23

    Speciality Chemicals Segment Highlights – H1 FY’23 Particulars 1 H1'FY22 H1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 600 863 44% Reported EBITDA 155 141 (9%)  Specialty Chemicals revenue grew by 44% on YoY basis driven by Reported EBITDA Margin (%) 25.9% 16.4% higher volume across product segments

  22. Slide 22: Nutrition & Health Solutions – Segment Snapshot

    Nutrition & Health Solutions – Segment Snapshot Global top 2 in Vitamin B3 Revenue Segmentation (H1’FY23) 5 Nutrition Ingredients & Domestic leader in Vitamin 100% in-house sourcing Domestic Sales for By End use B4 (Feed); Entered into of Beta Picoline (Key RM) for By Region Domestic Consumption Cos

  23. Slide 23: Nutrition & Health Solutions Segment Highlights – Q2 FY'23

    Nutrition & Health Solutions Segment Highlights – Q2 FY’23 1 FINANCIAL HIGHLIGHTS Particulars Q2'FY22 Q2'FY23 YoY (%) Revenue 179 114 (36%)  Nutritional Business revenue de-grew by 36%, on account of Reported EBITDA 35 14 (61%) lower demand owing to post flu impact and excess inventory Reported EBI

  24. Slide 24: Nutrition & Health Solutions Segment Highlights – H1 FY'23

    Nutrition & Health Solutions Segment Highlights – H1 FY’23 1 FINANCIAL HIGHLIGHTS Particulars H1'FY22 H1'FY23 YoY (%) Revenue 346 264 (24%)  Nutritional Business revenue de-grew by 24%, as the demand Reported EBITDA 61 32 (47%) was adversely impacted mainly due to impact of Bird & Swine Reported EB

  25. Slide 25: Chemical Intermediates – Segment Snapshot

    Chemical Intermediates – Segment Snapshot Entered Value added Region wise Revenue Segmentation Acetic Anhydride: 9 Products Globally No. 2 in derivative Propionic For Segment (H1’FY23) (Acetic Anhydride, Ethyl Domestic Sales for Merchant Mkt Anhydride to RoW 4% Acetate ,Propionic Anhydride, Internat

  26. Slide 26: Chemical Intermediates Segment Highlights – Q2 FY'23

    Chemical Intermediates Segment Highlights – Q2 FY’23 1 Particulars Q2'FY22 Q2'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 749 710 (5%) Reported EBITDA 103 76 (26%)  Chemical Intermediates revenue de-grew by 5% on YoY basis Reported EBITDA Margin (%) 13.8% 10.8% mainly due to input price of Acetic Aci

  27. Slide 27: Chemical Intermediates Segment Highlights – H1 FY'23

    Chemical Intermediates Segment Highlights – H1 FY’23 Particulars 1 H1'FY22 H1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 1,422 1,343 (6%)  Chemical Intermediates revenue de-grew by 6% on YoY basis Reported EBITDA 287 153 (47%) Reported EBITDA Margin (%) 20.2% 11.4%  Acetic Anhydride volume growth b

  28. Slide 28: Outlook & Growth Plans

    Outlook & Growth Plans

  29. Slide 29: Outlook

    Outlook  We expect our H2 performance to be better than H1, assuming no unexpected adverse situation.  We expect overall healthy revenue growth during FY’23, led by volume growth in Specialty Chemicals & Chemical intermediate business segment. Commissioning of our new capex during H2 is likely to

  30. Slide 30: Growth Capex Investment Plan – Business Wise

    Growth Capex Investment Plan – Business Wise (Already Committed & to be Committed) Additional Capex to be Committed during FY’23 & FY’24~ Rs. 1150 Crores Committed till date ~ Rs. 900 Crores Estimated Cash Outflow (From FY’22 to Q2’FY23, Total Cash Outflow ~ Rs. 422 Cr.) ~ (Rs. 363 Cr, Rs.650 Cr. &

  31. Slide 31: Capacity Build-Up Plan – FY'22 to FY'25

    Capacity Build- Up Plan – FY’22 to FY’25 (over Base of FY’22) Overall Capacity Build-Up Speciality Chemicals Capacity Build-Up Capacity Expansion Plan Capacity Expansion Plan (Overall capacity increase : 40.5% & CAGR: 12.0%) (Overall capacity increase: 44.7% & CAGR: 13.1%) 30.0% 32.3% 15.6% 1.5% 7.9

  32. Slide 32: Structural Shift towards Speciality via Growth Capex Plans

    Structural Shift towards Speciality via Growth Capex Plans Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality, Nutrition & Ot

  33. Slide 33: Quality, Business Excellence, Sustainability

    BUSINESS QUALITY SUSTAINABILITY EXCELLENCE

  34. Slide 34: Jubilant Ingrevia: Global Accreditation

    Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath Responsible Care    RC 14001:2015 ISO      9001:2015 ISO    22000:2005 ISO     14001:2015 ISO     45001:2018 FSSAI     FAMI-QS   HALAL    KOSHER   GMP State State FDA G

  35. Slide 35: Business Excellence and Digital Transformation

    Business Excellence and Digital Transformation Belt Competencies (FY’22) Digital Transformation Black Belts: 07 Green Belts: 103 Yellow Belts: 95  Our journey started in 2018 with an objective to improve Business Excellence  Operational efficiency Tools & Processes  Business & Supply chain proces

  36. Slide 36: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership

    Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership Mission: To develop multi-stakeholder sustainable Aspiring to touch 1 Million Established models to bring about ‘social change’ involving the Lives through in 2007 knowledge generation & sharing, experiential lives social in

  37. Slide 37: Sustainability Journey

    Sustainability Journey 2001 2002 2003 2005 2008 2009 2010 2013 2015 2019 2021 Climate Became GRI Change Became UNGC SoFI Sustainability Sustainability Sustainability Jubilant Bhartia 1st EvoVadis Dow Jones ISO ISO 14000 14000 Sustainability Organization Mitigation Signatory and Sustainability Goals

  38. Slide 38: Our Vision, Values, Promise and Philosophy

    Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing

  39. Slide 39: For More Information

    For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1000 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma

  40. Slide 40: Appendix I: Income Statement – Q2 & H1 FY23

    Appendix I: Income Statement – Q2 & H1 FY23 Particulars1 Q2'FY22 Q2'FY23 YoY (%) H1'FY22 H1'FY23 YoY (%) Total Revenue from Operations 1,223 1,304 7% 2,367 2,469 4% Speciality Chemicals 295 480 63% 600 863 44% Nutrition & Health Solutions 179 114 (36%) 346 264 (24%) Chemical Intermediates 749 710 (5

  41. Slide 41: Appendix II - Conference Call Details

    Appendix II - Conference Call Details Date : October 20, 2022 Time : 05:00 pm IST Diamond Pass Log-In To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, pass

Jubilant Ingrevia — Q2 FY2023 Earnings Presentation on 6ix